Latest technologies from University of Texas Health Science Center At Houstonhttp://uthealth.technologypublisher.comBe the first to know about the latest inventions and technologies available from University of Texas Health Science Center At Houstonen-USSat, 25 Oct 2014 01:42:53 GMTMon, 15 Sep 2014 11:14:44 GMThttp://blogs.law.harvard.edu/tech/rssuthsch-otm@uth.tmc.eduCopyright 2014, University of Texas Health Science Center At HoustonPhospholipid Associated 5-ASA for the Treatment of Inflammatory Bowel Diseasehttp://uthealth.technologypublisher.com/technology/15875 Inflammatory Bowel Disease (IBD) which represents a spectrum of diseases of the lower GI tract, notably Ulcerative Colitis (UC) and Crohn’s Disease (CD), is one of the most common gastrointestinal (GI) afflictions in the United States and Europe. It is also noteworthy that the incidence of UC has increased 2-3 fold in China and other counties in Asia adopting a more Westernized diet/lifestyle over the past decade. It has been estimated by the CDC that health care cost of $1.7 billion in the US are directly attributable to patients afflicted with UC and CD. When one includes los...Mon, 15 Sep 2014 11:14:44 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/15875Enterotoxigenic Escherichia coli Isolates Identified from Patients with Travelers' Diarrheahttp://uthealth.technologypublisher.com/technology/15419Tue, 24 Jun 2014 13:08:22 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/15419Human Neural Stem Cells Produced by Direct Programming from Somatic Cellshttp://uthealth.technologypublisher.com/technology/15021Thu, 10 Apr 2014 09:19:37 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/15021Antibiotic Microspheres For Treatment Of Infections And Osteomyelitishttp://uthealth.technologypublisher.com/technology/14790Thu, 20 Mar 2014 08:54:25 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/14790Multistage Nanoparticle Drug Delivery Systemshttp://uthealth.technologypublisher.com/technology/14758Fri, 14 Mar 2014 14:05:55 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/14758Virtual Mitral Valve Repairhttp://uthealth.technologypublisher.com/technology/14601Thu, 27 Feb 2014 11:53:29 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/14601Diagnostic and Method for Detection of Ankylosing Spondylitishttp://uthealth.technologypublisher.com/technology/12668Mon, 03 Jun 2013 11:44:10 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/12668Breathing-Controlled Electrical Stimulation for the Treatment of Neuropathic Pain and Spasticityhttp://uthealth.technologypublisher.com/technology/12511Thu, 09 May 2013 14:41:15 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/12511MEMS Based Blood Coagulometerhttp://uthealth.technologypublisher.com/technology/12393Fri, 26 Apr 2013 15:43:55 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/12393Novel Compounds and Methods of Use for the Treatment and Prevention of Cancer via Inhibition of the K-Ras Pathwayhttp://uthealth.technologypublisher.com/technology/12262Tue, 02 Apr 2013 13:33:12 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/12262Methods and composition for novel anti-cancer treatmentshttp://uthealth.technologypublisher.com/technology/12224Mon, 25 Mar 2013 09:38:08 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/12224Dual Function Airway Guidehttp://uthealth.technologypublisher.com/technology/11757Fri, 18 Jan 2013 15:22:36 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/11757Compositions and Methods for Regulation of Stem Cell Survival, Proliferation, and Differentiationhttp://uthealth.technologypublisher.com/technology/11691Wed, 09 Jan 2013 11:10:45 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/11691"Pedinap" - A Pediatric Anesthesia/Pharmacological Agent Induction Devicehttp://uthealth.technologypublisher.com/technology/11596Mon, 10 Dec 2012 15:41:06 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/11596USB Port Security And Access Control Softwarehttp://uthealth.technologypublisher.com/technology/11582Wed, 05 Dec 2012 07:10:22 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/11582Preparation and Use of Alveoar Cells to Treat Lung Disordershttp://uthealth.technologypublisher.com/technology/9854Mon, 23 Jul 2012 14:58:53 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/9854New Red Shifted Channelrhodopsins with Rapid Kineticshttp://uthealth.technologypublisher.com/technology/9557Fri, 15 Jun 2012 15:33:46 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/9557Cell line HAbeta 3-5http://uthealth.technologypublisher.com/technology/9139Wed, 28 Mar 2012 15:42:19 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/9139Anti-STAM Monoclonal Antibodieshttp://uthealth.technologypublisher.com/technology/8650Thu, 05 Jan 2012 12:30:18 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/8650Treatment and Prevention of Vascular Disease with Hybrid Cyclooxygenase:Eicosanoid Proteinshttp://uthealth.technologypublisher.com/technology/8258 Market: Some form of vascular disease effects one in four Americans, and costs for treatment reach into the billions. Prostanoids are an important, and emerging, therapeutic target in the campaign against vascular disease. Competitors and Current Problems: The prostanoid synthesis pathway is complicated, difficult to direct, and can have multiple end results, not all of them favorable. For example, some of the recent issues in the media and scientific community surrounding COX-2 inhibitors (such as increased potential of heart attacks among patients on COX-2 inhibitors) may involve u...Tue, 29 Nov 2011 09:53:17 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/8258Targeting Tumors by Pattern Recognition: A Paradigm shift in Targeted Therapeuticshttp://uthealth.technologypublisher.com/technology/8257 Market: The American Cancer Society estimates that more than 500,000 people will die from cancer in the U.S. in 2007. Many cancer deaths, specifically from cancers of the colon, breast, rectum, and uterine cervix cancers, could be significantly reduced with earlier detection and improved therapy. Cancer treatment of the 15 most common cancers accounted for an estimated $72.1 billion of medical expenditures in the US in 2004. World wide, IMS Health reported that drug companies exceeded $34 billion in sales of cancer drugs in 2006. Competitors and Current Problems: The holy grail of can...Tue, 29 Nov 2011 09:53:16 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/8257SUMO-Specific Protease Nucleotides and Proteins for Diagnosing Hyperpoliferative Diseaseshttp://uthealth.technologypublisher.com/technology/8256Market: Prostate cancer is the second most common cancer, and second leading cause of cancer death, in American men. The American Cancer Society predicts over 186,000 new diagnoses of prostate cancer, and over 28,000 deaths in the US in 2008. With early detection being key to a better prognosis, a significant number of people are demanding faster and more accurate diagnosis, and more targeted, efficient, and effective therapies. Competitors and Current Problems: One diagnostic of prostate cancer is by the PSA blood tests. Unfortunately, if higher than normal levels of PSA are detected ...Tue, 29 Nov 2011 09:53:16 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/8256Structure of Proline- and Arginine-Rich Peptides that Lead to Inhibition of Inflammation and Induction of Angiogenesishttp://uthealth.technologypublisher.com/technology/8255The Technology: PR39, a naturally produced proline-and-arginine-rich peptide consisting of 39 amino acids, induces angiogenesis and reduces inflammation in mouse models. Through structural and biochemical investigations of PR11, a truncated form of PR39, researchers at the University of Texas Health Science Center at Houston (UTHSC-H) have identified that the 20S proteasome-inhibiting activity of PR39 depends on specific amino acids and structural characteristics. They have also discovered a novel 12-amino acid peptide that has comparable activity as PR39. The linear amino acid sequenc...Tue, 29 Nov 2011 09:53:15 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/8255Ribonucleotide Preparations and Methods for the Promotion of Wound Healinghttp://uthealth.technologypublisher.com/technology/8252Tue, 29 Nov 2011 09:53:14 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/8252Resuscitation From Shockhttp://uthealth.technologypublisher.com/technology/8251Market: The Clinical Decision Support System (CDSS) market in Europe alone is estimated to grow to near $430.7 billion by 2012. The American Hospital Association (AHA) reported in a 2006 survey that the number of hospitals adopting moderate to high use of IT systems in general increased 37% from 2005. With more than $37 million patient admissions in 2006 to AHA registered hospitals, the market for increased IT adoption, including CDSS, has very lucrative potential. Competitors and Current Problems: Shock resuscitation after severe injury and blood loss is an emergent effort to regain n...Tue, 29 Nov 2011 09:53:13 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/8251Modulation of Small Biomolecule Levels for the Treatment of Priapism and Erectile Dysfunctionhttp://uthealth.technologypublisher.com/technology/8249Tue, 29 Nov 2011 09:53:12 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/8249Mesodermal-Like Cells for Treatment Of Ischemiahttp://uthealth.technologypublisher.com/technology/8248Market: Peripheral artery disease affects 8-12 million Americans. Patients experience pain, numbness, and ulcers. Mobility can be affected, and gangrene can set in. It is estimated that there are 150,000 amputations each year in the United States is due to critical leg ischemia. Of those, the peri-operative mortality rate for below the knee amputations is 5-10%, with a 15-20% peri-operative mortality rate for above the knee amputations. In addition, it is estimated that 30% of first time amputees will require a second amputation. Further, patients with critical limb ischemia have an el...Tue, 29 Nov 2011 09:53:11 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/8248Bone Graft Scaffolds with High-Strength and High-Porosityhttp://uthealth.technologypublisher.com/technology/8247Tue, 29 Nov 2011 09:53:11 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/8247HRS/HRS-2 Polyclonal Antibodyhttp://uthealth.technologypublisher.com/technology/8125 Polyclonal Antibodies Against HRS The Technology: Dr. Andrew Bean at the University of Texas Health Science Center at Houston (UTHealth) has developed a polyclonal antibody to Hrs. Hrs is a protein that plays a role in the growth factor signaling pathways. Cellular expression of hrs-2 can be determined via the polyclonal Hrs antibody. This antibody will be useful in determining the relationship between growth factor receptor tyrosine kinases and tyrosine phosphorylation of Hrs. Publications:• Growth factor-induced tyrosine phosphorylation of Hrs, a novel 115-kilodalton protein with a...Thu, 03 Nov 2011 09:50:43 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/8125Inhibitors of Cyclic Nucleotide Synthesis and Their Usehttp://uthealth.technologypublisher.com/technology/8124 Market: The over production of cyclic nucleotides such as cGMP and cAMP are critical factors in many diseases. The most common causes of diarrhea in humans and animals are mediated by elevated cGMP and are induced by toxins of pathogenic bacteria. The need for novel therapies for both the human and veterinary medical fields is tremendous. Diarrheal diseases are among the worlds leading causes of death, especially in children. The pathology resulting from edema factor of B. anthracis is mediated by cAMP and while antibiotics kill the organism itself, it is often the accumulated edema fa...Thu, 03 Nov 2011 09:50:00 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/8124Novel Bisphosphonate Formulation with Therapeutic Use in Osteoporosishttp://uthealth.technologypublisher.com/technology/8123 Market: There is a large market demand for therapeutic compounds addressing bone disease. Osteoporosis, osteitis deformans, or Paget’s disease, bone metastasis, multiple myeloma, and others result in bone fragility. It is noted that metastases to the bone occur in up to 75% of breast and prostate cancers. Of the above listed bone diseases, osteoporosis is a major indication with thirty-five million people in the seven major pharmaceutical markets (U.S., France, Germany, Italy, Spain, UK, and Japan) afflicted by osteoporosis. With this type of demand, it is not surprising that a recent...Thu, 03 Nov 2011 09:49:12 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/8123Immuno-Diagnosis of Lyme Diseasehttp://uthealth.technologypublisher.com/technology/8119Thu, 03 Nov 2011 09:42:16 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/8119A Method for Generating Poroelastograms in Vivohttp://uthealth.technologypublisher.com/technology/8078Mon, 24 Oct 2011 09:15:59 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/8078Application of constitutively active soluble guanylyl cyclase (sGC) in prevention of cGMP-dependent pathophysiology and drug developmenthttp://uthealth.technologypublisher.com/technology/8071 Treatment Or Prevention Of Cgmp-Dependent Pathophysiology With A Mutant Variant Of A Soluble Guanylyl Cyclase Market: The technology has the potential to reach a multitude of markets, such as: cardiovascular disease, treatment and prevention of tumors, treatment of penile dysfunction, and treatment of septic shock. Competitors and Current Problems: It is known that soluble guanylyl cyclase (sGC) is an important enzyme that is involved in the regulation of cardiovascular homeostasis and pathologies (blood pressure, atherosclerosis, and septic shock), neurotransmission and sensory percep...Wed, 19 Oct 2011 08:27:05 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/8071Paclitaxel Resistant and Dependent Cell Lineshttp://uthealth.technologypublisher.com/technology/8070 The Technology: Dr. Fernando Cabral at the University of Texas Health Science Center at Houston (UTHealth) has developed a series of mutant cell lines with altered sensitivity to antimitotic drugs. Paclitaxel is a drug that binds to polymerized tubulin and inhibits microtubule disassembly. One of the major limitations in using these drugs, however, is the emergence of drug resistant tumor cells. The inventor has found that some tubulin isotypes alter sensitivity to antimitotic drugs by perturbing microtubule assembly, while others have little effect on assembly but increase the binding...Wed, 19 Oct 2011 08:27:05 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/8070<![CDATA[OV-1 & OV-6 Hybridoma]]>http://uthealth.technologypublisher.com/technology/8068Wed, 19 Oct 2011 08:27:04 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/8068Mouse Embryonic Stem Cell Line EZ-BL6http://uthealth.technologypublisher.com/technology/8067 Mouse Embryonic Stem Cell Line EZ-BL6 The Technology: Researchers at the University of Texas Health Science Center at Houston (UTHealth) have developed complement anaphylatoxin C5a-deficient mice via the disruption of the C5aR gene. It is becoming increasingly clear that C5aR plays an important role in the regulation of many physiological and cellular responses characteristic of acute shock and that the C3aR functions to temper the immune response in acute shock. This well-characterized model lacks the complement C5a, making it an excellent model for studying the relationship between C...Wed, 19 Oct 2011 08:27:04 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/8067HRS/HRS-2 Monoclonal Antibodyhttp://uthealth.technologypublisher.com/technology/8066 Monoclonal Antibodies Against HRS-2 The Technology: Dr. Andrew Bean at the University of Texas Health Science Center at Houston (UTHealth) has developed a monoclonal antibody to Hrs-2. Hrs-2 is a protein that plays a role in the formation and dissolution of protein complexes during vesicular formation. Cellular expression of hrs-2 can be determined via the monoclonal hrs-2 antibody. This antibody will be useful in determining how hrs-2 is regulated and tracking hrs-2 interaction during vesicular trafficking. Publications:• The cellular and developmental expression of hrs-2 in rat. Eur...Wed, 19 Oct 2011 08:27:03 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/8066E. coli strain AD93/pTMG3 (lacking phosphatidylethanolamine (PE) and contain a-monoglucosyldiacylglycerol MGlcDAG))http://uthealth.technologypublisher.com/technology/8065 Modified E. coli Strain AD93/pTMG3 The Technology: Dr. William Dowhan at the University of Texas Health Science Center at Houston (UTHealth) has developed a bacterial strain to construct null mutants in specific steps of phospholipid biosynthesis. The anionic phospholipid (phosphatidylglycerol and cardiolipin) content of the mitochondria can be varied and controlled in these mutants. This bacterial strain lacks phosphatidylethanolamine (PE) and contains monoglucosyldiacylglycerol. At present, the role of individual phospholipids in specific membrane functions is not completely underst...Wed, 19 Oct 2011 08:27:03 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/8065Factor B KO Mouse on C57/BL/6 Genetic Backgroundhttp://uthealth.technologypublisher.com/technology/8064 Factor B KO Mouse on C57/Bl/6 Genetic Background The Technology: Researchers at the University of Texas Health Science Center at Houston (UTHealth) have developed complement factor B-deficient mice on C57Black6 background via the disruption of the murine Bf, exon 3 through exon 7. It is becoming increasingly clear that factor B plays an important role in the regulation of the alternative complement pathway. The role of factor B in disease pathogenesis, however, is unclear. This well-characterized model lacks the complement factor B, making it an excellent model for studying the role of...Wed, 19 Oct 2011 08:27:02 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/8064E. coli strain JA200 carrying plasmid pPS3155-lambda (JA200/pPS3155-A)http://uthealth.technologypublisher.com/technology/8063 E. coli Strain JA200 Carrying Plasmid pPS3155-lambda The Technology: Dr. William Dowhan at the University of Texas Health Science Center at Houston (UTHealth) has developed a bacterial strain to construct null mutants in specific steps of phospholipid biosynthesis. The anionic phospholipid (phosphatidylglycerol and cardiolipin) content of the mitochondria can be varied and controlled in these mutants. This bacterial strain lacks phosphatidylethanolamine (PE) and contains monoglucosyldiacylglycerol. At present, the role of individual phospholipids in specific membrane functions is not c...Wed, 19 Oct 2011 08:27:02 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/8063Cells with variable beta-tubulin compositionhttp://uthealth.technologypublisher.com/technology/8062Wed, 19 Oct 2011 08:27:01 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/8062C5a Receptor "Knock out" Micehttp://uthealth.technologypublisher.com/technology/8061 C5a Receptor "Knock out" Mice The Technology: A researcher at the University of Texas Health Science Center at Houston (UTHealth) has developed complement anaphylatoxin C5a receptor-deficient mice on C57Black6 genetic background via the disruption of the C5aR gene. It is becoming increasingly clear that C5aR plays an important role in the regulation of many physiological and cellular responses characteristic of acute shock and that the C3aR functions to temper the immune response in acute shock. This well-characterized model lacks the complement C5a, making it an excellent model for st...Wed, 19 Oct 2011 08:27:01 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/8061C3a Receptor "Knock out" Micehttp://uthealth.technologypublisher.com/technology/8060 C3a Receptor "Knock Out" Mice Market: Global sales of asthma and COPD treatments are currently worth around US$20 billion. In the US asthma affected 29.5 million people in 2005. Asthmatics visited the doctor in offices and outpatient clinics 14.6 million times in 2004, and there were 1.8 million visits to the emergency room. Unfortunately, asthma was the cause of death for 3,780 people in the US in 2004. There is a significant and growing market looking for earlier diagnosis and better treatment options. The Technology: A researcher at the University of Texas Health Science Center at H...Wed, 19 Oct 2011 08:27:00 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/8060Bacterial Strain (AD93/pDD72) with Altered Phospholipid Composition for the Production Cardiolipinhttp://uthealth.technologypublisher.com/technology/8059 Bacterial Strain with Altered Phospholipid Composition for the Production of Cardiolipin The Technology: Dr. William Dowhan at the University of Texas Health Science Center at Houston (UTHSC-H) has developed a bacterial strain to construct null mutants in specific steps of phospholipid biosynthesis. The anionic phospholipid (phosphatidylglycerol and cardiolipin) content of the mitochondria can be varied and controlled in these mutants. Cardiolipin is an essential lipid of the mitochondria and until recently has been understudied as to function and regulation of synthesis because of the...Wed, 19 Oct 2011 08:27:00 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/8059Antipeptide antibodies which recognize specific somastatin receptor subtypeshttp://uthealth.technologypublisher.com/technology/8058 Antipeptide Antibodies That Recognize Specific Somatostatin Receptor Subtypes The Technology: This patent covers: 1. A method for developing somatostatin receptor subtype specific antibodies. 2. Antibodies developed using this method to identify somatostatin receptor subtypes belonging to the seven transmembrane domain receptor family. 3. The use of these antibodies, alone or in kit form, to identify somatostatin receptors in tissues or protein extracts. The utility of the patented technology is founded upon its ability to selectively identify somatostatin receptor subtypes and thus w...Wed, 19 Oct 2011 08:26:59 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/8058Anti Sentrin Antibodyhttp://uthealth.technologypublisher.com/technology/8057 Anti-Sentrin (Sumo-1) Polyclonal Antibody Background: Small Ubiquitin-like Modifier (SUMO) is a family of proteins that modify other proteins by attaching and detaching covalently. SUMO modification of proteins has many functions, including protein stability, nuclear-cytosolic transport, and transcriptional regulation. Such fundamental activities lead to potential market impact in a wide array of fields such as oncology, immunology, and metabolics. The Technology : Dr. Edward Yeh at the University of Texas Health Science Center at Houston (UTHealth) has developed an anti-Sentrin polycl...Wed, 19 Oct 2011 08:26:59 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/8057Anti-OPN Polyclonal Antiserahttp://uthealth.technologypublisher.com/technology/8056 Anti-OPN Polyclonal Antisera The Technology: Researchers at the University of Texas Health Science Center at Houston (UTHSC-H) have developed methods and compositions to analyze and study sialic rich proteins found in osteopontin (OPN), a type of mineralized tissue containing non-collagenous proteins. More specifically, Western immunoblots were performed with anti-OPN polyclonal antisera raised from rabbits. OPN has never been detected in dentin extracts by Western immunoblotting until now, making the antisera an excellent tool for further research into the formation of bone and denti...Wed, 19 Oct 2011 08:26:58 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/8056Anti NEDD8 Antibodyhttp://uthealth.technologypublisher.com/technology/8055 Anti-NEDD8 Monoclonal Antibody Market: Regulation of the cell cycle involves steps that are critical to cell survival, including the detection and repair of genetic damage as well as the prevention of uncontrolled cell division. Studies on the cell cycle impact huge market sectors such as oncology. Background: Neural precursor cell expressed, developmentally down-regulated 8 (NEDD8) is a ubiquitin-like protein that modulates the cullin subunits of SCF ubiquitin E3 ligases. NEDDylation of the cullins is required for recruitment of E2 to the ligase complex, facilitating ubiquitin conjugat...Wed, 19 Oct 2011 08:26:58 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/8055Adenosine Deaminase Deficient Transgenic Mice: Testing Ground for Asthma Therapieshttp://uthealth.technologypublisher.com/technology/8054 Adenosine Deaminase Deficient Transgenic Mice and Methods and Uses Thereof Market: Restrictive lung disease, including asthma, SCID, chronic obstructive pulmonary disease (COPD), and pulmonary fibrosis, is a prevalent condition. In the US asthma affected 29.5 million people in 2005. Asthmatics visited the doctor in offices and outpatient clinics 14.6 million times in 2004, and there were 1.8 million visits to the emergency room. Unfortunately, asthma was the cause of death for 3,780 people in the US in 2004. Likewise, COPD, including emphysema and chronic bronchitis, affect many people...Wed, 19 Oct 2011 08:26:57 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/8054Enhancing MRI Contrast by Geometric Confinement of Small Imaging Agents within Nanoporous Particleshttp://uthealth.technologypublisher.com/technology/8053Wed, 19 Oct 2011 07:45:34 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/8053Thioaptamer oligonucleotide ligands against endothelial E-selectin protein.http://uthealth.technologypublisher.com/technology/8052Wed, 19 Oct 2011 07:45:34 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/8052Method to perform Axial-shear strain imaging for tumor classificationhttp://uthealth.technologypublisher.com/technology/8051Tue, 18 Oct 2011 16:04:55 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/8051Liposome-mediated transfection of genes in central nervous system cellshttp://uthealth.technologypublisher.com/technology/7773Market: According to the Center for Disease Control, at least 1.4 million people sustain a traumatic brain injury each year in the United States. Of these about 50,000 die, 250,000 are hospitalized, and 1.1 million are treated and released from emergency departments. Those who survive the initial trauma must fight the risk of the secondary effects from brain injury, which includes the loss of brain cells due to increased brain edema, uncontrollable intracranial pressure, production of free radicals and toxic molecules, and the loss of neurofilament proteins following injury. Current Pro...Mon, 22 Aug 2011 16:19:49 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/7773Inhibitors of C-Reactive Protein Induced Vascular Inflammation and Their Usehttp://uthealth.technologypublisher.com/technology/7770Market: Information collected by the Centers for Disease Control and Prevention during 2006 showed that cardiovascular disease (CVD) from all causes accounts for 29% of deaths worldwide and ranks second only to infectious and parasitic diseases. In the United States alone, atherosclerosis reportedly affects one in four persons, causing approximately 42% of all deaths. With a market size of more than $15 billion, the market for novel atherosclerosis therapies has very lucrative potential. Competitors and Current Problems: Inflammatory response plays an important role in the onset, develo...Mon, 22 Aug 2011 16:19:47 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/7770Immunosupportive Drug Sparing Diethttp://uthealth.technologypublisher.com/technology/7769 Introduction: This invention is directed to the field of nutritional medicine. Namely, it describes a diet that is immunosupportive, but also inhibits the P450 enzyme in the gut, thus increasing drug bioavailability. Current Problems: For many patients on an immunosuppressive drug regimen, there is a balance of priorities that must occur. The immunosuppressive drugs save the life of the patient by, for instance, preventing organ rejection. On the other hand, the drugs leave the patient vulnerable to secondary infections and must be taken in sufficient doses to ensure there is an adequ...Mon, 22 Aug 2011 16:19:46 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/7769Hyperplastic Vasculomyopathy Diagnostichttp://uthealth.technologypublisher.com/technology/7767 Market: In 2007 in the United States alone, it is estimated that direct and indirect costs of cardiovascular diseases is $481.8 billion. Each year hundreds of thousands of patients are diagnosed with vascular diseases such as myocardial infarction and stroke. Competitors and Current Problems: A subset of individuals may have a genetic predisposition to vascular diseases. The ability to screen and identify individuals and their family members who are at risk for vascular disease will allow for preventative therapies (medical and surgical therapies), life-style modifications, and awaren...Mon, 22 Aug 2011 16:19:45 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/7767Gastro-Protective Compounds Potentially Useful To Treat Ulcer Diseasehttp://uthealth.technologypublisher.com/technology/7766 Market: The CDC estimates 25 million Americans suffer from gastric ulcers. One in ten Americans will develop gastric ulcers in their lifetime. The CDC further estimates 1 million hospitalizations and 6,500 deaths due to this condition. All this leads to a huge market. Business Week placed the global anti-ulcer market at over $8 billion. Competitors and Current Problems: It is unsurprising given the size of the market to find current therapeutics on the market. However, current medications are not without side effects. Chronic administration of H2 agonists can lead to increased gastric ...Mon, 22 Aug 2011 16:19:44 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/7766Elastography: Highly Sensitive Ultrasound Imaging of Tissue Elasticity In Vivo for Detection and Evaluation of Breast Cancer and Other Elastic Abnormalitieshttp://uthealth.technologypublisher.com/technology/7733 Market: Market reports indicate that the ultrasound market in Europe was estimated at $719.0 million in 2006, with growth expected to reach $1 billion in 2013. Similarly, the ultrasound market in the United States was estimated at $1.27 billion in 2003. With an estimated 31.2 million patient exams in 2004 conducted by traditional clinical ultrasound segments alone, in addition to the recent adoption of ultrasound imaging by new user groups including surgeons, anesthesiologists, and emergency physicians, the ultrasound market is expected to continue to spur rapid new growth.Current Prob...Mon, 08 Aug 2011 15:34:50 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/7733Methods and Compositions for the Detection of Functional Clostridium Difficile Toxinshttp://uthealth.technologypublisher.com/technology/7307Thu, 30 Jun 2011 14:03:10 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/7307Heat Treatment of Inflamed Tissuehttp://uthealth.technologypublisher.com/technology/6610 Market: Coronary artery disease is a leading cause of death in industrialized countries. It is manifested by atherosclerotic plaques, which are thickened areas in vessel walls made up of an accumulation of cholesterol, proliferating smooth muscle cells and inflammatory cells. In 2004, it was reported that over 1 million Americans underwent an angioplasty procedure to correct the build up of these plaques, contributing partly to interventional cardiology market revenue in excess of $4 billion. Competitors and Current Problems: Many techniques have been developed to identify and remove t...Tue, 22 Mar 2011 08:15:07 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/6610Device to Prevent Nocturnal Drying of the Oral Cavityhttp://uthealth.technologypublisher.com/technology/6609Tue, 22 Mar 2011 08:07:39 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/6609Automated Catheter Insertion Systemhttp://uthealth.technologypublisher.com/technology/6608 Market: Robotic assisted surgeries are on the rise, up from generally 20,000 robotic assisted procedures in the United States in 2005, to 80,000 robotic assisted prostatectomy procedures alone in 2009. Such robotic assisted surgeries allow for greater precision, smaller incisions and therefore less patient blood loss and quicker patient recovery, but require a highly skilled robotic operator for efficient implementation. Prices of existing surgical systems range from $700,000 to $2.25 million per system, and their presence in hospitals has increased by more than 400% since 2004. Compet...Tue, 22 Mar 2011 08:01:31 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/6608Device for ERG (Electro-Retinogram) Spectral Perimetryhttp://uthealth.technologypublisher.com/technology/6606Tue, 22 Mar 2011 07:52:59 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/6606Collagen-binding Proteins from Enterococcal Bacteriahttp://uthealth.technologypublisher.com/technology/6413Wed, 02 Feb 2011 13:08:22 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/6413Apparatus and Method for Palpographic Characterization of Vulnerable Plaque and Other Biological Tissuehttp://uthealth.technologypublisher.com/technology/6412Wed, 02 Feb 2011 13:08:22 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/6412A Novel Calpain-Like Cysteine Protease in Type 2 Diabeteshttp://uthealth.technologypublisher.com/technology/6411 Market: The World Health Organization (WHO) has estimated that the diabetes 2 market will more than double by 2030. In the United States type 2 diabetes affected 20.8 million people in the year 2000. The number of patients diagnosed with diabetes 2 has been continuously increasing. Approximately 90% of all diabetes cases in the United States are of type 2. With a market size of more than $11.2 billion in the US alone, there is a significant and growing market looking for better treatment options. Competitors and Current Problems: Genome-wide screens for susceptibility genes for complex...Wed, 02 Feb 2011 13:08:21 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/6411Atherosclerosis-Prone Mouse Modelshttp://uthealth.technologypublisher.com/technology/5881Tue, 19 Oct 2010 07:18:11 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/5881Alertness Monitoring: A Perceptual Chronometer Device and Method for Measuring Fitness-For-Duty (FFD)http://uthealth.technologypublisher.com/technology/5880Tue, 19 Oct 2010 07:14:24 GMTuthsch-otm@uth.tmc.eduhttp://uthealth.technologypublisher.com/technology/5880